Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Trading 08-10 12:19:59 EDT

81.81

+0.52

+0.64%

High82.05	Low81.22	Vol318.37M
Open81.29	D1 Closing81.29	Amplitude1.01%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O6.43B	T/O Rate--	Tradable Shares0.00
P/B7.759012	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":81.809296,"timestamp":1786378798933,"preClose":81.28564,"halted":0,"volume":318370128,"delay":0,"changeRate":0.006442,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":0.523659,"latestTime":"08-10 12:19:59 EDT","open":81.28592,"high":82.048,"low":81.224785,"amount":6431492623.867668,"amplitude":0.010127,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786392000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.759012,"peRate":-93.260942,"turnoverRate":0.009057,"increases":227,"decrements":268,"flats":21,"marketCap":2089167320143.75,"floatMarketCap":1904203861185.875},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"2658893993","title":"Plus Therapeutics Inc Expected to Post a Loss of 91 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893993","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893993?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:49","pubTimestamp":1786366145,"startTime":"0","endTime":"0","summary":"Plus Therapeutics Inc <CNSY.OQ> expected to post a loss of91cents a share - Earnings PreviewPlus Therapeutics IncCNSY.OQCNSY.Ois expected to  show a fall in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44710O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658396419","title":"Shares of Vertex Pharma up 7.7% Premarket After Rival Genetic Disorder Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2658396419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658396419?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:47","pubTimestamp":1786366034,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4N4470WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TBXU","BK4585","LU0289739699.SGD","SG9999013999.USD","LU2324357040.USD","LU0889565916.HKD","LU1430594728.SGD","LU2362541273.HKD","LU0320765992.SGD","VRTX","IBB","LU1585245621.USD","IE00B19Z3B42.SGD","IE0009355771.USD","BK4139","LU0432979614.USD","IDNA","LU2417539215.USD","LU0058720904.USD","SG9999001176.USD","BIB","LU2362541513.USD","IE00B19Z9Z06.USD","PBE","LU2362540622.SGD","IE00B2B36J28.USD","LU1093756325.SGD","LU1035775433.USD","SGXZ57979304.SGD","BK4532","LU2456880835.USD","IE00BZ9MQY76.HKD","IE0002141913.USD","GNMX","LU2237438978.USD","IE00BJT1NW94.SGD","IE00B19Z3581.USD","BK4567","BBH","IBBQ","IE0002270589.USD","LU0256863811.USD","IE00BJJMRZ35.SGD","LU1778281490.HKD","LU2468319806.SGD","LU0417517546.SGD","LU0079474960.USD","LU2236285917.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993969","title":"Tenax Therapeutics Exec Says Two Deaths Occurred During Double-Blind Phase, with Investigators Determining Both were Unrelated to Tnx-103- Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993969","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993969?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:46","pubTimestamp":1786365987,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470FJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TENX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939571","title":"Inhibikase Therapeutics, Inc. Expected to Post a Loss of 11 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939571","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939571?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:44","pubTimestamp":1786365845,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics, Inc. <IKT.OQ> expected to post a loss of11cents a share - Earnings PreviewInhibikase Therapeutics, Inc.IKT.OQIKT.Ois expected to  show no change in quarterly revenue when it r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44710G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658532939","title":"Ireland's Theravance Biopharma Q2 Revenue Rises 11% but Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658532939","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658532939?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:42","pubTimestamp":1786365751,"startTime":"0","endTime":"0","summary":"Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimatesOverviewIreland-based specialty pharma's Q2 revenue rose 11% yr/yr but missed analyst expectationsAdjusted net income for Q2 bea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","LU0289739343.SGD","LU0124676726.USD","LU0154245673.USD","LU0203345920.USD","LU0511384066.AUD","BK4007","ZYME","BK4149","TBPH","CMI","LU0154245756.USD","LU0289961442.SGD","LU0069063385.USD","MADE","BK4588","LU0057025933.USD","LU0689626769.HKD","HRTX","LU0472753341.HKD","BK4139","BK4585","IE000M9KFDE8.USD","BK4567","BK4533","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658510939","title":"Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Vanda (VNDA) and AbCellera Biologics (ABCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658510939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658510939?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:40","pubTimestamp":1786365614,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novo Nordisk (NVO), Vanda (VNDA) and AbCellera Biologics (ABCL). ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-vanda-vnda-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-novo-nordisk-nvo-vanda-vnda-and-abcellera-biologics-abcl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4007","IE00BZ1G4Q59.USD","THNR","NVOH","NVO","NVOX","BK4139","OZEM","BK4535","LU1093756168.USD","LU1093756325.SGD","LU0154236417.USD","ABCL","IE00BKVL7J92.USD","BK4599","BK4532","PPH","BK4585","VNDA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939827","title":"AIM ImmunoTech Q2 EPS $-0.43","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939827?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:37","pubTimestamp":1786365466,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXN83PKF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4557","AIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658393839","title":"Cogent Biosciences Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2658393839","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658393839?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:37","pubTimestamp":1786365426,"startTime":"0","endTime":"0","summary":"Cogent Biosciences  reported Monday its Q2 loss widened to $96.4 million from a loss of $73.5 million a year earlier.Analysts polled by FactSet expected a loss of $98 million.As of June 30, the company said it had $792.3 million in cash, cash equivalents and marketable securities and expected it could fund operations into late 2028.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4139","LU1670627923.USD","LU1670628061.USD","COGT","CANC","LFSC","BK4089","BK4505","CCOI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939896","title":"Press Release: AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Toward Planned Phase 3 Development in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939896","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939896?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:36","pubTimestamp":1786365360,"startTime":"0","endTime":"0","summary":"DURIPANC study evaluating Ampligen in combination with AstraZeneca's. -- Engaged Thermo Fisher Scientific's PPD clinical research business to. support study design of a planned pivotal Phase 3 clinical trial in. -- Maintained encouraging observations from Erasmus MC Cancer Institute,survival trends, and consistently reported high quality of life among. -- Strengthened the Company's balance sheet through multiple financing. -- Successfully regained full compliance with NYSE American's continued. -- Planning government-focused initiatives to evaluate Ampligen's antiviral. potential against Ebola virus disease, consistent with the Company's","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","BK4557","BK4022","AIM","R","BK4232","MEDX","HYLG","GDOC","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658193988","title":"Kura Oncology Highlights Ziftomenib Preclinical Activity, Menin Binding Profile in Blood Publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2658193988","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658193988?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:33","pubTimestamp":1786365180,"startTime":"0","endTime":"0","summary":"Kura Oncology highlights ziftomenib preclinical activity, menin binding profile in Blood publicationKura Oncology highlighted a new Blood publication detailing the discovery and preclinical profile of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL9W50GH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","BK4139","BK4112","BK4505","LU0314104364.USD","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014013.SGD","LU2210149790.SGD","SG9999014005.SGD","BCDF","IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","KURA","IE00BN0W2W23.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658360599","title":"NanoViricides, Inc: Received Regulatory Approval for a Phase Ii Clinical Trial of Nv-387 Oral Gummies as a Treatment for Ebola in DR Congo","url":"https://stock-news.laohu8.com/highlight/detail?id=2658360599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658360599?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:31","pubTimestamp":1786365105,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470NZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NNVC","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936014","title":"NanoViricides Wins DRC Approval for Phase II Trial of NV-387 Oral Gummies for Ebola Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936014","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936014?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:31","pubTimestamp":1786365085,"startTime":"0","endTime":"0","summary":"NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatmentNanoViricides won ACOREP clearance in DR Congo to launch a Phase II trial of NV-387 oral gummies for Bundib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLccfVb3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","NNVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658033936","title":"Capricor Therapeutics Updates Financial Calendar with Q2 Results Release, Conference Call and Webcast Scheduled","url":"https://stock-news.laohu8.com/highlight/detail?id=2658033936","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658033936?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:30","pubTimestamp":1786365049,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics updates financial calendar with Q2 results release, conference call and webcast scheduledCapricor schedules second-quarter 2026 results release for Aug. 13, 2026.Conference call,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL9zN4Qk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4112","IE00BGHQF748.EUR","LU2210150020.SGD","BK4588","BK4585","IE00BKPKM429.USD","SG9999014013.SGD","NDAQ","BK4139","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","BCDF","CAPR","IE00BN0W2V16.EUR","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936774","title":"Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936774?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:30","pubTimestamp":1786365001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA6M0CTN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CAPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936030","title":"B. Riley Adjusts Zymeworks Price Target to $44 From $40, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936030","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936030?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:29","pubTimestamp":1786364965,"startTime":"0","endTime":"0","summary":"B. Riley Adjusts Zymeworks Price Target to $44 From $40, Maintains Buy Rating","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936449","title":"Sight Sciences Names Kashif Rashid Chief Legal Officer, Replacing Jeremy Hayden","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936449","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936449?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:22","pubTimestamp":1786364555,"startTime":"0","endTime":"0","summary":"Sight Sciences names Kashif Rashid chief legal officer, replacing Jeremy HaydenSight Sciences named Kashif Rashid chief legal officer, corporate secretary effective Aug. 10, 2026.Rashid previously ser","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL9DFFnr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004303.SGD","LU0289739699.SGD","BK4533","ATRA","BK4139","IE0009355771.USD","IE0002141913.USD","LU0432979614.USD","LU1989763427.SGD","LU0266013472.USD","TMED","SGHT","GEHC","BK4585","SGXZ23171101.USD","LU1721429402.USD","LU0114720955.EUR","BK4568","LU1914381329.SGD","BK4539","BK4566","LU1023059063.AUD","LU1691799644.USD","LU1721429741.USD","LU1989763690.USD","BK4082","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LGHT","LU2211815571.USD","LU1057294990.SGD","LU0124676726.USD","LU2468319806.SGD","PJP","BK4588","LU0234572021.USD","LU0882574055.USD","ABT","LU2133065610.SGD","LU1061106388.HKD","LU0689626769.HKD","BK4592","LU2237957811.SGD","SGXZ41872573.SGD","IHI","LU2089984988.USD","LU0122379950.USD","LU0058720904.USD","BK4504","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936420","title":"Immix Biopharma is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936420","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936420?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:19","pubTimestamp":1786364340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936655","title":"Silo Pharma Wins European Patent for PTSD Prevention Therapy SPC-15","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936655?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:15","pubTimestamp":1786364115,"startTime":"0","endTime":"0","summary":"Silo Pharma wins European patent for PTSD prevention therapy SPC-15Silo Pharma won a European patent for its lead PTSD candidate SPC-15, a preventative intranasal, nose-to-brain therapy targeting stre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL3kVg76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4588","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SILO","BK4139","BK4585","IE00BN0W2T93.GBP","LU2095319765.USD","BK4112","IE00B64PRP62.GBP","BCDF","LU0314104364.USD","IE00BN0W2V16.EUR","BK4202","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658693668","title":"Silo Pharma Granted European Patent Covering Novel Ptsd Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2658693668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658693668?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:15","pubTimestamp":1786364108,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470SY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4202","BK4139","SILO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658365389","title":"Cogent Biosciences Q2 Net Income USD -96.405 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658365389","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658365389?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:13","pubTimestamp":1786363990,"startTime":"0","endTime":"0","summary":"Aug 10 (Reuters) - Cogent Biosciences Q2 income from operations USD -102.638 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 10-AUG-202611:47:52.75 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nRSDb7xYB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","CANC","COGT","LFSC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction